banner-bg banner-bg
dr-ashutosh-jaiswal

Dr. Ashutosh Jaiswal

Consultant

DrNB Medical Oncology - National Board of Examination in Medical Sciences (Dharamshila Narayana Superspeciality Hospital), DNB General Medicine, MBBS - LLRM Medical College Meerut

Book appointment

Select Month

September
October

Select Date

Book Appointment
commo-btn-up-arrow
About Dr. Ashutosh Jaiswal

Dr. Ashutosh Jaiswal is a highly qualified medical oncologist with expertise in chemotherapy, immunotherapy, targeted therapy, and bone marrow transplant. A graduate of LLRM Medical College, he holds a DNB in General Medicine and a DrNB in Medical Oncology. He has trained at renowned institutions such as AIIMS, Rajiv Gandhi Cancer Institute and Research Center (RGCIRC), and BLK-Max Hospital. Internationally certified by the European Society for Medical Oncology (ESMO), Dr. Jaiswal is known for delivering comprehensive, compassionate cancer care through a multidisciplinary approach.

Specialization And Expertise

Breast Cancer

Lung Cancer

Chemotherapy, Immunotherapy and Targeted Therapy

Multiple Myeloma/Lymphoma

Gastrointestinal and Genitourinary Cancers

Milestones Achieved

2025

Delivering diverse chemotherapy protocols, immunotherapy, targeted therapies, and bone marrow transplant, successfully treating cancer patients from a variety of backgrounds while contributing to oncology research and maintaining ESMO-certified global standards.

2025

Received STS from the Indian Council of Medical Research.

2025

Selected to attend Certificate of competence in Lymphoma from European Society of Oncology and completed.

Publication

Prevention and Management of Complications of Androgen Deprivation  Therapy for the Treatment of Cancer of the Prostate. (2024),1, Page(s)263-272; Complications of Cancer Therapy: Best  Practices in Prevention and Management.  Springer, Singapore. https://doi.org/10.1007/978- 981-99-0984- 1_22.

Are we there RET?- Jaiswal, Ashutosh; Chanana, Raajit. Are we there, RET? Cancer Research, Statistics, and Treatment 5(1):p 175-176, Jan–Mar 2022. | DOI: 10.4103/crst.crst_28_22.

×
Back to top
×

Request Call Back



× Disclaimer Image
×

Share Profile Via